{"id":2816,"date":"2024-03-01T11:44:18","date_gmt":"2024-03-01T11:44:18","guid":{"rendered":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/?p=2816"},"modified":"2024-03-13T12:54:24","modified_gmt":"2024-03-13T12:54:24","slug":"ovarian-cancer-awareness-month-and-valtive1","status":"publish","type":"post","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/ovarian-cancer-awareness-month-and-valtive1\/","title":{"rendered":"Ovarian Cancer Awareness Month And VALTIVE1"},"content":{"rendered":"<p style=\"font-weight: 400\"><strong>Ovarian cancer awareness month<\/strong><\/p>\n<p style=\"font-weight: 400\">March is Ovarian Cancer Awareness Month. In this global campaign aiming at raising awareness, promoting research, fundraising, and supporting women with ovarian cancer around the world, we would like to introduce you to the <a href=\"https:\/\/www.cardiff.ac.uk\/centre-for-trials-research\/research\/studies-and-trials\/view\/valtive1\" target=\"_blank\" rel=\"noopener\">VALTIVE1<\/a> study, one of the ovarian cancer trials that the <a href=\"https:\/\/www.cardiff.ac.uk\/centre-for-trials-research\" target=\"_blank\" rel=\"noopener\">Centre for Trials Research at Cardiff University<\/a> is running.<\/p>\n<p style=\"font-weight: 400\">When a doctor prescribes a drug to their patient for treating their cancer, neither the doctor nor the patient know for sure if it will work. Some patients may complete the treatment plan, whereas some others will stop it earlier, if their additional symptoms and further investigations show that the tumour has escaped the control of the drug and has started growing. Until then, the patient may go through a number of unpleasant side effects that any cancer treatment inevitably causes.<\/p>\n<p><em>Would it be good if a test could tell the doctor and the patient whether the prescribed drug is working before the treatment plan is completed or the side effects become unbearable?<\/em><\/p>\n<p style=\"font-weight: 400\">In the <a href=\"https:\/\/www.cardiff.ac.uk\/centre-for-trials-research\/research\/studies-and-trials\/view\/valtive1\" target=\"_blank\" rel=\"noopener\">VALTIVE1<\/a> study, we\u2019re studying a blood test (biomarker) in ovarian cancer that may answer this question.<\/p>\n<p style=\"font-weight: 400\">The usual treatment for ovarian cancer is a combination of surgery and chemotherapy followed by a drug called bevacizumab that is administered through an injection for up to a year to keep the cancer under control and delay cancer growth. Bevacizumab works well for some people with ovarian cancer but not for all; it can cause side effects and requires regular trips to the hospital for the administration.<\/p>\n<p style=\"font-weight: 400\">The VALTIVE researchers have discovered a blood test which can tell doctors after a few weeks of starting treatment whether bevacizumab is working or not. These findings need to be checked though before this test is available on the NHS, so the team is running a small study (VALTIVE1), where women being treated with bevacizumab for their ovarian cancer donate their blood samples during routine blood tests that patients have when going to the hospital. If the study confirms the initial fundings, a larger study (VALTIVE2) will be conducted for proving conclusively the value of this blood test.<\/p>\n<p style=\"font-weight: 400\">The advantage for patients is that stopping an ineffective drug early allows alternatives (if available) to be used instead, and saves the patient from multiple visits to hospital as well as the side effects of an ineffective treatment. On the other hand, if the patient\u2019s cancer remains under control at the end of the standard 12 months, we will be able to argue that the patient should be entitled to continue bevacizumab for as long as they benefit.<\/p>\n<p style=\"font-weight: 400\">Chief Investigator: Prof Gordon Jayson, Professor of Medica Oncology, The University of Manchester and The Christie NHS Foundation Trust<\/p>\n<p style=\"font-weight: 400\">Funder: Cancer Research UK<\/p>\n<p style=\"font-weight: 400\">Sponsor: The University of Manchester<\/p>\n<p style=\"font-weight: 400\">Coordinating centre: Centre for Trials Research<\/p>\n<p style=\"font-weight: 400\">IRAS ID number: 285116<\/p>\n<p style=\"font-weight: 400\">VALTIVE1 Team email address: <a href=\"mailto:VALTIVE@cardiff.ac.uk\">VALTIVE@cardiff.ac.uk<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Ovarian cancer awareness month March is Ovarian Cancer Awareness Month. In this global campaign aiming at raising awareness, promoting research, fundraising, and supporting women with ovarian cancer around the world, [&hellip;]","protected":false},"author":1698,"featured_media":2817,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-2816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7dIou-Jq","jetpack-related-posts":[{"id":2896,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/the-piccos-study-evaluating-anti-cancer-drug-delivery\/","url_meta":{"origin":2816,"position":0},"title":"The PICCOS Study: Evaluating Anti-Cancer Drug Delivery","author":"Rebecca Hamilton","date":"April 24, 2024","format":false,"excerpt":"Study Name: Pressurised IntraPeritoneal Aerosolised Chemotherapy (PIPAC) in the management of cancer of the colon, ovary and stomach: a randomised controlled phase II trial of efficacy in peritoneal metastases (PICCOS for short). Background The study is funded by NIHR EME (Efficacy and Mechanism Evaluation) Programme Grant to treat patients with\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"PIPAC training image","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":152,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/pin-a-trial-looking-at-olaparib-for-non-small-cell-lung-cancer\/","url_meta":{"origin":2816,"position":1},"title":"PIN: A Trial Looking At Olaparib For Non Small Cell Lung Cancer","author":"Joanna Canham","date":"April 13, 2016","format":false,"excerpt":"In 2013, there were 45,525 new cases of lung cancer in the UK and it kills around 35,000 annually (Source: CRUK). Non-small cell lung cancer (NSCLC) accounts for around 87% of all lung cancer. NSCLC is one of the leading causes of death worldwide and presents a huge health economic\u2026","rel":"","context":"In &quot;Cancer Trial&quot;","block_context":{"text":"Cancer Trial","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/cancer-trial\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2076,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/clinical-trials-units-are-uniting-together-to-take-on-a-virtual-moveathon-for-cancer-research-uk\/","url_meta":{"origin":2816,"position":2},"title":"Clinical Trials Units Are Uniting Together To Take On A Virtual Moveathon For Cancer Research UK","author":"Richard Haggerty","date":"May 25, 2021","format":false,"excerpt":"Professor Richard Adams, director of clinical research in Cardiff co-founded the MOVEATHON back in 2019, his team set-up this initiative to not only raise vital funds for life-saving research but to increase awareness of clinical trials and thank all the families and patients who take part in trials. Cardiff, Southampton,\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/05\/CRUK-Sponsored-Bike-Ride-6.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/05\/CRUK-Sponsored-Bike-Ride-6.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/05\/CRUK-Sponsored-Bike-Ride-6.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/05\/CRUK-Sponsored-Bike-Ride-6.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/05\/CRUK-Sponsored-Bike-Ride-6.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/05\/CRUK-Sponsored-Bike-Ride-6.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1137,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/international-conference-on-communication-in-healthcare-icch-porto-portugal-1-4-sept-2018\/","url_meta":{"origin":2816,"position":3},"title":"International Conference on Communication in Healthcare (ICCH), Porto, Portugal 1-4 Sept 2018","author":"Denitza Williams","date":"September 10, 2018","format":false,"excerpt":"About the conference The recent International Conference on Communication in Healthcare (ICCH)\u00a0brought together researchers, teachers, practitioners and policy makers from around the world to explore and to improve all aspects of communication in healthcare.\u00a0 This was a great conference for our researchers at the Division of Population Medicine,\u00a0the\u00a0Centre for Trials\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/09\/team-cardiff.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/09\/team-cardiff.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/09\/team-cardiff.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/09\/team-cardiff.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/09\/team-cardiff.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/09\/team-cardiff.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2734,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/faktion-and-the-breast-cancer-drug-paving-a-future-for-hormonal-therapies\/","url_meta":{"origin":2816,"position":4},"title":"FAKTION And The Breast Cancer Drug Paving A Future For Hormonal Therapies","author":"Margherita Carucci","date":"November 29, 2023","format":false,"excerpt":"- by Margherita Carucci and Angela Casbard on behalf of the FAKTION CTR Team When a patient is diagnosed with cancer, their doctor will prescribe a drug or a combination of drugs for destroying or keeping the cancer cells under control. But how do doctors know which drugs are the\u2026","rel":"","context":"In &quot;Events&quot;","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1676,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/my-asco-centre-for-trials-research-at-the-american-society-of-clinical-oncology-2019\/","url_meta":{"origin":2816,"position":5},"title":"My ASCO: Centre for Trials Research at the American Society of Clinical Oncology 2019","author":"Margherita Carucci","date":"July 25, 2019","format":false,"excerpt":"Background This year I\u2019ve had the great opportunity to attend ASCO (American Society of Clinical Oncology) conference as a Centre for Trials Research representative together with Professor Richard Adams, Director Cancer Division, and Catrin Cox for the presentation of the FAKTION study by the Chief Investigators (CIs), Dr Sacha Howell\u2026","rel":"","context":"In &quot;Cancer Trial&quot;","block_context":{"text":"Cancer Trial","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/cancer-trial\/"},"img":{"alt_text":"Centre for Trials Research at ASCO","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2019\/07\/IMG-20190604-WA0002.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2019\/07\/IMG-20190604-WA0002.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2019\/07\/IMG-20190604-WA0002.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2019\/07\/IMG-20190604-WA0002.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2019\/07\/IMG-20190604-WA0002.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2019\/07\/IMG-20190604-WA0002.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"meta_box":[],"jetpack_featured_media_url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/03\/oca-2455641215.jpg","_links":{"self":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/users\/1698"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/comments?post=2816"}],"version-history":[{"count":4,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2816\/revisions"}],"predecessor-version":[{"id":2821,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2816\/revisions\/2821"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media\/2817"}],"wp:attachment":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media?parent=2816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/categories?post=2816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/tags?post=2816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}